December 6th 2024
Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
November 23rd 2024
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
November 22nd 2024
Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.
AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
New Therapies Cry Out for New Skills
There are positive indications for future growth.
AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion
With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.
Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
Ultragenyx Picks Andelyn Biosciences to Manufacture Novel Gene Therapy for Sanfilippo Syndrome
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
Daiichi Sankyo Partners with Depixus to Accelerate RNA-Targeted Drug Discovery
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
NightHawk Biosciences Shifts into a Pure-Play Large-Molecule CDMO
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
RoslinCT to Manufacture CRISPR-Based Gene Therapy Casgevy
RoslinCT will manufacture Vertex Pharmaceuticals’ CRISPR-based gene therapy, Casgevy, recently approved for treating sickle cell disease and β thalassemia.
Sanofi to Terminate Rare Disease Drug Licensing Agreement with Maze Therapeutics in Wake of FTC’s Challenge
Sanofi has issued a statement expressing its disappointment with FTC’s decision to block an exclusive licensing agreement with Maze Therapeutics for a rare disease drug candidate.
AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion
AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).
AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies
This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.
Training for Operational Excellence
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
The Dislocation of Progress
Pharmaceuticals are entering a transition into a far more complex era of patient therapies, and patient segmentation.
Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development
Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.
Lithuania Set to Become Home to Largest Biotech City
The largest biotech hub is set to be built in Lithuania by Northway Group.
Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals
Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.
Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies
Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.
Salary Survey for Pharma Scientists Shows Increase of 6.7% Since 2022
A recent AAPS Salary Survey shows a rising trend in compensation for pharmaceutical scientists since 2022.
CPHI Annual Report: VC Capital Investment and Contract Services Growth in 2024
The report indicates a rise in biotech funding and subsequent growth for pharma contract services.
Royalty Pharma to Purchase up to $1.5 Billion of PTC Therapeutics’ Royalty on Roche’s Evrysdi
The spinal muscular atrophy treatment, currently marketed by Roche, generated $1.2 billion in sales in 2022.
Spark Therapeutics Partners with SpliceBio on a Gene Therapy for Eye Disease
Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.
CIRM Picks Forge Biologics as AAV Manufacturing Partner
The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.
Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.
Bristol Myers Squibb Acquires Mirati Therapeutics for up to $5.8 Billion
Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.
Salipro Biotech and Icosagen to Collaborate on Antibody Discovery
Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.
BIOVECTRA in Tech Transfer Agreement with Acuitas Therapeutics for LNP Delivery System
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases
Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.
Novartis Completes Sandoz Spin-off
Spinning off Sandoz allows Novartis to focus on the areas of cardiovascular, immunology, renal and metabolic, and oncology.
Millions Raised for the Development of Precision Oncology Platform
Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.